NCT07476326 2026-03-17Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With MelanomaBiocon LimitedPhase 1 Not yet recruiting120 enrolled
NCT06934616 2025-04-30A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid TumorsGenor Biopharma Co., Ltd.Phase 1 Not yet recruiting330 enrolled